BC
UTHR icon

Bridgefront Capital’s United Therapeutics UTHR Stock Holding History

Bridgefront Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$789K Buy
1,457
+923
+173% +$520K 0.21% 159
2026
Q1 		$317K Sell
534
-3,941
-88% -$1.96M 0.08% 381
2025
Q4 		$2.18M Buy
4,475
+1,767
+65% +$823K 0.55% 30
2025
Q3 		$1.14M Sell
2,708
-583
-18% -$196K 0.33% 69
2025
Q2 		$946K Buy
+3,291
New +$984K 0.25% 113
2024
Q1 		– Sell
-925
Closed -$203K – 566
2023
Q4 		$203K Buy
+925
New +$213K 0.15% 294
2022
Q4 		– Sell
-1,467
Closed -$307K – 526
2022
Q3 		$307K Buy
+1,467
New +$328K 0.31% 127

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Bridgefront Capital's UTHR Position: Q2 2026 in Review

Bridgefront Capital increased its United Therapeutics (UTHR) stake by 173% in Q2 2026, buying an estimated $520K and bringing the position to 1,457 shares worth $789K. The position accounts for 0.21% of the portfolio, ranked #159.

Bridgefront Capital first reported a position in UTHR in Q3 2022 and has held it in 7 quarters since. The position peaked at $2.18M in Q4 2025. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Bridgefront Capital held 1,457 shares of United Therapeutics worth $789K as of Q2 2026.
  • Bridgefront Capital bought 923 United Therapeutics shares in Q2 2026, an estimated $520K.
  • United Therapeutics made up 0.21% of Bridgefront Capital's portfolio in Q2 2026, its #159 holding.
  • Bridgefront Capital first reported a position in United Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • Bridgefront Capital's United Therapeutics position peaked at $2.18M in Q4 2025.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.